Filing Flows › Sarepta Therapeutics (SRPT) › Q2 2026 › vs Q2 2025
Sarepta Therapeutics (SRPT) Q2 2026 vs Q2 2025 (year over year)
Sarepta Therapeutics's revenue fell $210M (-34%) from $611M in Q2 2025 to $401M in Q2 2026. The biggest changes: Elevidys −$184M (-65%); Other revenues −$25.4M (-26%); Pmo Products −$708K (-0.3%).
Sarepta Therapeutics, Q2 2026: revenue $401M (-34% year over year), operating margin 3.3%, net loss $4.9M, operating cash flow $197M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 49.0% | 37.6% | +11.4 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Pmo Products | $231M | $231M | −$708K | -0.3% |
| Elevidys | $98.1M | $282M | −$184M | -65% |
| Other revenues | $72.6M | $98.0M | −$25.4M | -26% |
| Revenue | $401M | $611M | −$210M | -34% |
| Net loss | $4.9M | −$197M | $202M | — |
| Costs & expenses | $406M | $692M | −$286M | -41% |
| Operating costs | $388M | $496M | −$108M | -22% |
| Interest & other, net | $15.0M | −$38.1M | $53.1M | — |
| Income tax | $3.1M | −$43.3M | $46.4M | — |
| Operating cash sources | $202M | $64.4M | $138M | +213% |
| Depreciation & amortization | $10.4M | $10.8M | −$431K | -4% |
| Share-based compensation | $24.5M | $37.0M | −$12.6M | -34% |
| Working capital & other | $167M | $16.6M | $150M | +908% |
| Net loss absorbed | $4.9M | −$197M | $202M | — |
| Operating cash flow | $197M | $261M | −$64.3M | -25% |
| Free cash flow (OCF − capex) | $197M | $230M | −$33.0M | -14% |
| Capital expenditures | $555K | $31.8M | −$31.2M | -98% |
Questions
How much did Sarepta Therapeutics's revenue grow year over year in Q2 2026?
Sarepta Therapeutics's revenue fell $210M (-34%) from $611M in Q2 2025 to $401M in Q2 2026.
What drove Sarepta Therapeutics's revenue change in Q2 2026?
Elevidys −$184M (-65%); Other revenues −$25.4M (-26%); Pmo Products −$708K (-0.3%).